These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 29941327)
21. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Kaaijk P; Luytjes W; Rots NY Hum Vaccin Immunother; 2013 Jun; 9(6):1263-7. PubMed ID: 23442726 [TBL] [Abstract][Full Text] [Related]
22. Passive and active immunization against respiratory syncytial virus for the young and old. Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961 [TBL] [Abstract][Full Text] [Related]
23. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633 [TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study. Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062 [TBL] [Abstract][Full Text] [Related]
25. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573 [TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus seasonality and its implications on prevention strategies. Janet S; Broad J; Snape MD Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014 [TBL] [Abstract][Full Text] [Related]
27. Clinical and epidemiologic features of respiratory syncytial virus. Hall CB; Simőes EA; Anderson LJ Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683 [TBL] [Abstract][Full Text] [Related]
28. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs. Garg R; Latimer L; Wang Y; Simko E; Gerdts V; Potter A; van Drunen Littel-van den Hurk S Vaccine; 2016 Jan; 34(2):261-269. PubMed ID: 26616551 [TBL] [Abstract][Full Text] [Related]
29. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
30. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233 [TBL] [Abstract][Full Text] [Related]
31. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239 [TBL] [Abstract][Full Text] [Related]
32. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings. Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701 [TBL] [Abstract][Full Text] [Related]
33. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959 [TBL] [Abstract][Full Text] [Related]
34. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320 [TBL] [Abstract][Full Text] [Related]
35. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries. Atwell JE; Lutz CS; Sparrow EG; Feikin DR Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783 [TBL] [Abstract][Full Text] [Related]
36. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related]
37. Maternal RSV vaccine development. Where to from here? Gunatilaka A; Giles ML Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565 [TBL] [Abstract][Full Text] [Related]
38. The path to an RSV vaccine. Shaw CA; Ciarlet M; Cooper BW; Dionigi L; Keith P; O'Brien KB; Rafie-Kolpin M; Dormitzer PR Curr Opin Virol; 2013 Jun; 3(3):332-42. PubMed ID: 23727193 [TBL] [Abstract][Full Text] [Related]